Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,076 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
Nagamachi Y, Yamauchi N, Muramatsu H, Miyajima N, Inomata H, Okamoto T, Nozawa E, Gotoh Y, Koyama R, Ihara K, Nishisato T, Kato J. Nagamachi Y, et al. Among authors: okamoto t. Rinsho Ketsueki. 2015 Mar;56(3):323-8. doi: 10.11406/rinketsu.56.323. Rinsho Ketsueki. 2015. PMID: 25876787 Japanese.
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, Miyamoto H, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Okuda T, Minami S, Takahashi M, Okamoto T, Takada K, Miyanisi K, Takayama T, Kato J. Uemura N, et al. Among authors: okamoto k, okamoto t. Cancer Chemother Pharmacol. 2017 Oct;80(4):707-713. doi: 10.1007/s00280-017-3404-8. Epub 2017 Aug 28. Cancer Chemother Pharmacol. 2017. PMID: 28849257 Clinical Trial.
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
Sato Y, Hirakawa M, Ohnuma H, Takahashi M, Okamoto T, Okamoto K, Miyamoto H, Muguruma N, Furuhata T, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: okamoto k, okamoto t. Cancer Chemother Pharmacol. 2017 Dec;80(6):1133-1139. doi: 10.1007/s00280-017-3458-7. Epub 2017 Oct 16. Cancer Chemother Pharmacol. 2017. PMID: 29038850
[Anaphylactic reaction to oxaliplatin--a case of colon cancer].
Sagawa T, Sato Y, Abe S, Okuda T, Araki N, Takahari D, Okamoto T, Takayama T, Kato J, Niitsu Y. Sagawa T, et al. Among authors: okamoto t. Gan To Kagaku Ryoho. 2006 Dec;33(13):2093-6. Gan To Kagaku Ryoho. 2006. PMID: 17197761 Japanese.
Iron chelator deferasirox rescued mice from Fas-induced fulminant hepatitis.
Sato T, Kobune M, Murase K, Kado Y, Okamoto T, Tanaka S, Kikuchi S, Nagashima H, Kawano Y, Takada K, Iyama S, Miyanishi K, Sato Y, Takimoto R, Kato J. Sato T, et al. Among authors: okamoto t. Hepatol Res. 2011 Jul;41(7):660-7. doi: 10.1111/j.1872-034X.2011.00821.x. Hepatol Res. 2011. PMID: 21711425
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Sato Y, Takayama T, Sagawa T, Okamoto T, Miyanishi K, Sato T, Araki H, Iyama S, Abe S, Murase K, Takimoto R, Nagakura H, Hareyama M, Kato J, Niitsu Y. Sato Y, et al. Among authors: okamoto t. Cancer Chemother Pharmacol. 2006 Nov;58(5):570-6. doi: 10.1007/s00280-006-0193-x. Epub 2006 Feb 4. Cancer Chemother Pharmacol. 2006. PMID: 16463059 Clinical Trial.
4,076 results